Glenmark’s innovative pipeline is focused on three core therapeutic areas: oncology, dermatology and respiratory. Our pipeline demonstrates our efforts to solve some of medicine’s most difficult challenges and discover molecular entities that will have a major impact on how people live. With more than 350 scientists dedicated to new chemical entity (NCE) research and more than 100 scientists involved in new biologic entity (NBE) research, we have developed an enviable and robust pipeline anchored in first- and best-in-class discovery. With 4 NBEs, 3 NCEs and a biosimilar candidate in various stages of clinical development, Glenmark is delivering on its commitment to bring the best science to patients worldwide. Glenmark thanks all the volunteers who participate in our clinical trials. They are vital to our research advancement. To learn more about our clinical trials, please visit www.clinicaltrials.gov.
HER2 positive cancers such as breast cancer, gastric cancer & ovarian cancer
A HER2xCD3 bispecific antibody (bsAb,) is the first clinical candidate based on Glenmark’s proprietary BEAT® platform. Preclinical study results from redirected lysis assays suggest GBR 1302, in comparison to current 1st and 2nd line HER2-targeted monoclonal antibodies, exhibits faster and more complete killing of HER2+ tumor cells. GBR 1302 is in development for HER2 positive cancers.
A CD38xCD3 bispecific antibody (bsAb) based on Glenmark’s proprietary BEAT® platform targets CD38. Preclinical study results suggest GBR 1342 has a potent antitumor effect on patient-derived multiple myeloma cell lines. GBR 1342 targets CD38 positive tumors including hematologic malignancies and solid tumors.
An EGFRxCD3 bispecific antibody (bsAb) based on Glenmark’s proprietary BEAT® platform. GBR 1372 targets EGRF positive tumors, including those resistant to standard of care.
GBR 830 is an anti-OX40 monoclonal antibody that inhibits activated T cells and effector memory T cells that are involved in a variety of autoimmune and chronic inflammatory disorders. The lead indication being evaluated for GBR 830 is moderate-to-severe atopic dermatitis (AD).
An inhibitor of the Retinoid-related Orphan Receptor gamma t (ROR γ t), GRC 39815 is currently in preclinical studies for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Steroid + AH
* Olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg), formerly GSP 301 nasal spray is an investigational, fixed-dose combination spray administered intra-nasally for the potential treatment of seasonal allergic rhinitis in adults and children. Glenmark submitted a NDA for Ryaltris to the FDA in May 2018.
* Ryaltris™(olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg), has been conditionally accepted by the FDA as the brand name.
A long-acting muscarinic antagonist (tiotropium bromide) administered by nebulization for the long-term, once-daily maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD).
A recombinant DNA-derived, humanized monoclonal antibody, biosimilar of Omalizumab (trade name Xolair) being developed for the treatment of asthma and chronic idiopathic urticaria (CIU). The pharmacokinetics of GBR 310 are being studied compared to its reference product and, if approved, GBR 310 could be among the first biosimilar for a respiratory or allergic disease in the US.
Glenmark’s pipeline also includes GRC 27864, a potential candidate for the treatment of chronic inflammatory conditions; GRC 4039, a PDE 4 inhibitor in development as a potential candidate for rheumatoid arthritis; and GBR 910, an anti-TL1A immunological antibody. GRC 27864 is currently in Phase 2 development ex-US and is a candidate for out-licensing.